share_log

B. Riley Securities Maintains Buy on Journey Medical, Lowers Price Target to $3

Benzinga ·  May 23, 2023 20:59

B. Riley Securities analyst Kalpit Patel maintains Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $6 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment